Physician profile
Michael Kent Vandenberg
NPI 1396728085
$23,825.65
in general payments reported to CMS, 2019-2025
39 companies · $3,038 in 2025
The $3,038 reported for 2025 was more than what 77% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,919 · 2020: $2,553 · 2021: $3,593 · 2022: $3,765 · 2023: $4,199 · 2024: $3,758 · 2025: $3,038.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,766.41 |
| Education | $228.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,469.24 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $4,022.60 | 2019-2025 | Evenity, Prolia, Enbrel |
| Novartis Pharmaceuticals Corporation | $1,781.28 | 2019-2025 | |
| Ucb, INC. | $1,654.05 | 2019-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $1,424.16 | 2019-2025 | Tremfya |
| Glaxosmithkline, LLC. | $1,345.20 | 2019-2025 | Benlysta |
| Pfizer INC. | $1,150.33 | 2019-2025 | |
| Radius Health, INC. | $985.01 | 2019-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $961.77 | 2019-2025 | Ofev, Cyltezo |
| Lilly USA, LLC | $865.02 | 2019-2025 | Taltz |
| Mallinckrodt Hospital Products INC. | $855.43 | 2021-2025 | Acthar |
| Horizon Therapeutics Plc | $665.02 | 2019-2023 | Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $542.22 | 2020-2025 | Sotyktu, Orencia |
| Aurinia Pharma U.S., INC. | $504.50 | 2021-2025 | Lupkynis |
| Astrazeneca Pharmaceuticals LP | $483.94 | 2021-2025 | Saphnelo |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $385.23 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $298.12 | 2019-2024 | Strensiq |
| Regeneron Healthcare Solutions, INC. | $227.32 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $171.31 | 2019 | |
| Sobi, INC | $127.09 | 2019-2022 | |
| Genentech USA, INC. | $125.01 | 2019-2025 | Gazyva, Actemra |
| Fresenius Kabi USA, LLC | $116.84 | 2023-2024 | Idacio |
| Kiniksa Pharmaceuticals International, Plc | $94.37 | 2024 | Arcalyst |
| Octapharma USA, INC. | $80.42 | 2023-2024 | Octagam Immune Globulin (Human) |
| Celgene Corporation | $75.92 | 2019 | |
| Organon LLC | $52.97 | 2023-2025 | Hadlima |
| Pacira Therapeutics, INC. | $41.28 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $40.93 | 2023-2024 | Crysvita |
| Ferring Pharmaceuticals INC. | $37.07 | 2025 | Euflexxa |
| Janssen Pharmaceuticals, INC | $35.99 | 2025 | Tremfya |
| Sandoz INC. | $29.73 | 2023 | Hyrimoz |
| Beigene USA, INC. | $27.39 | 2025 | Brukinsa |
| United Therapeutics Corporation | $24.84 | 2024 | Tyvaso |
| Abbott Laboratories | $24.84 | 2025 | Eterna |
| Merck Sharp & Dohme LLC | $24.52 | 2019 | |
| Sanofi-Aventis U.S. LLC | $24.38 | 2021 | |
| Celltrion USA INC. | $18.67 | 2025 | Vegzelma |
| Bioventus LLC | $16.41 | 2024 | Durolane |
| Scilex Pharmaceuticals INC. | $15.23 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Vandenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.